Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily, which regulates transcription of target genes in a ligand-dependent manner. Ligands for PPARgamma have been shown to attenuate proliferation of vascular smooth muscle cells, and to induce apoptosis in several cell lines in vitro. Since monocrotaline (MCT)-induced pulmonary hypertension in rats is characterized by proliferation of pulmonary vascular smooth muscle cells, we hypothesized that PPARgamma ligands may reduce MCT-induced pulmonary hypertension. To test this hypothesis, we treated MCT-injected rats with pioglitazone and troglitazone, synthetic ligands for PPARgamma, for three weeks and measured pulmonary artery pressure and pulmonary vessel wall thickness. TdT-mediated dUTP-biotin nick end labeling (TUNEL) and immunostaining for proliferating cell nuclear antigen (PCNA) were utilized to assess apoptosis and cell proliferation in the pulmonary arterial walls of pioglitazone-treated rats. MCT with pioglitazone or troglitazone treatment significantly reduced pulmonary hypertension and wall thickening of the pulmonary arteries. TUNEL-positive apoptotic cells were not seen in the pulmonary arterial walls of either MCT-injected or control rats with or without pioglitazone. PCNA-positive cells were only seen in the thickened pulmonary arterial walls of MCT rats, but not in the pulmonary arterial walls of controls and of pioglitazone-treated MCT rats. We conclude that PPARgamma ligands reduce MCT-induced pulmonary hypertension and pulmonary vascular wall thickening in rats. Inhibition of MCT-induced cell proliferation in the pulmonary arterial walls may account for this effect
Download full-text PDF |
Source |
---|
Int J Emerg Med
January 2025
Departamento de Cardiología, Fundación Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia.
Background: Penetrating cardiac trauma is an entity with high pre and intrahospital mortality due to complications such as cardiac tamponade and massive hemothorax. A ventricular septal defect (VSD) occurs in 1-5% of cases and can present early or late. The management strategy for VSD resulting from penetrating cardiac trauma is uncertain.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Catheter-based pulmonary artery denervation (PADN) has achieved promising outcomes to treat pulmonary hypertension (PH). We herein present stereotactic body radiotherapy (SBRT) as a novel noninvasive approach for PADN. A single fraction of 15 Gy, 20 Gy or 25 Gy was delivered for PADN in a thromboxane A2 (TxA2) - induced acute PH swine model.
View Article and Find Full Text PDFInt J Cardiol
January 2025
State Key Laboratory for Innovation and Transformation of Luobing Theory, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address:
Background: Heart failure (HF) is a high-burden clinical syndrome characterized by intravascular and extravascular congestion, impacting patients' outcomes. Current diagnostic methods for assessing intravascular congestion, including right heart catheterization (RHC), have some limitations. There is a need for accurate, stable, and widely applicable non-invasive measurement methods to improve HF diagnosis and treatment.
View Article and Find Full Text PDFAnn Pharm Fr
January 2025
SVKM's NMIMS School of Pharmacy and Technology Management Shirpur, Dhule, India-425405, India; SVKM Institute of Pharmacy, Dhule, Maharashtra-424001, India. Electronic address:
Objective: The beneficial usefulness is limited because of its deprived solubility and bioavailability. The recent work deals with the advancement of solid lipid nanoparticles of Ambrisentan for the effective therapy of pulmonary hypertension intended for oral delivery.
Material And Methods: The solid lipid nanoparticles of Ambrisentan were developed using the melt-emulsification method.
Heart Rhythm
January 2025
Department of Cardiology, The affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Background: A significant proportion of patients with isolated atrial flutter (AFL) will develop atrial fibrillation (AF) following cavotricuspid isthmus (CTI) ablation.
Objective: To determine whether concomitant pulmonary vein isolation (PVI) could reduce the incidence of new-onset atrial fibrillation (NOAF) in the setting of inducible AF following CTI ablation.
Methods: A total of 275 consecutive patients with isolated AFL who successfully underwent CTI ablation were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!